Epigenetic Differences May Explain Lack of Response to Metastatic Melanoma Immunotherapy | GenomeWeb

CHICAGO (GenomeWeb) – A study by researchers at the NYU Langone Medical Center and the Moffitt Cancer Center suggests tumor infiltrating cells (TIL) differ epigenetically in individuals with metastatic melanoma who do or do not respond to adoptive T cell therapy based around these TILs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.